Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) has become the first drug to be approved by the US Food and Drug Administration (FDA) as a treatment for noncirrhotic nonalcoholic ...

but US biotech Madrigal Pharma thinks it now has enough evidence for its drug resmetirom to support regulatory filings. The Massachusetts company has reported the results of the phase 3 MAESTRO ...

Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...

Resmetirom has received Breakthrough Therapy designation from the FDA and could be the first approved treatment for patients with NASH with liver fibrosis. Dr. Stephen Harrison, the lead ...

Rezdiffra (resmetirom), a once-daily, oral and liver-directed THR-β agonist. Rezdiffra gained the FDA’s accelerated approval in March 2024 for adult patients with nonalcoholic steatohepatitis ...

Madrigal Pharma has become the first drugmaker to claim FDA approval for a drug to treat ... s oral THR β-selective agonist Rezdiffra (resmetirom) for adults with MASH – also known as non ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...